These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 360353)
21. [Further experiences with the Imurek treatment in multiple sclerosis]. Müller J; Sauermann W; Kreiner R Psychiatr Neurol Med Psychol (Leipz); 1981 Sep; 33(9):527-31. PubMed ID: 7302005 [TBL] [Abstract][Full Text] [Related]
22. Comparative clinical trial of cyclosporine in multiple sclerosis: the pros. Dommasch D Neurology; 1988 Jul; 38(7 Suppl 2):28-9. PubMed ID: 3290711 [TBL] [Abstract][Full Text] [Related]
23. A comprehensive protocol for clinical trials in multiple sclerosis which favored azathioprine and corticosteroid as a type of treatment for the chronic progressive phase. Tourtellotte WW; Syndulko K; Baumhefner RW; Shapshak P; Osborne M Neurology; 1988 Jul; 38(7 Suppl 2):83-6. PubMed ID: 3386848 [No Abstract] [Full Text] [Related]
24. A preliminary evaluation of azathioprine (Imuran) in the treatment of multiple sclerosis. Tucker WG; Kapphahn KH Henry Ford Hosp Med J; 1969; 17(2):89-92. PubMed ID: 5783817 [No Abstract] [Full Text] [Related]
25. [Initial experiences with the Reiber 1979 determination of autochthonous IgG production within the scope of clinical and immunologic follow-up studies in multiple sclerosis treated with immunosuppressive therapy]. Dachsel R; Köppel C Psychiatr Neurol Med Psychol (Leipz); 1989 Jul; 41(7):420-5. PubMed ID: 2772076 [TBL] [Abstract][Full Text] [Related]
26. [Immunosuppressive therapy of multiple sclerosis using cyclosporin A and azathioprine. Long-term effects, risks, proton spin tomography and immunological findings]. Kappos L Schriftenr Neurol; 1990; 32():1-200. PubMed ID: 2200108 [No Abstract] [Full Text] [Related]
27. [Efficacy and tolerance of cyclosporin A in the treatment of multiple sclerosis]. Schluep M; Steck AJ; Despland PA; Regli F; Ochsner F; Berrut E; Gauthier G Schweiz Rundsch Med Prax; 1991 Jun; 80(24):670-2. PubMed ID: 2068440 [TBL] [Abstract][Full Text] [Related]
30. [New proposals for the treatment of multiple sclerosis. Preliminary study]. Floris V; Spadaro M Riv Neurol; 1985; 55(3):169-84. PubMed ID: 4035256 [TBL] [Abstract][Full Text] [Related]
31. Further observations on the effect of azathioprine on chronic nonremitting multiple sclerosis. Rosen JA Trans Am Neurol Assoc; 1978; 103():209-12. PubMed ID: 757060 [No Abstract] [Full Text] [Related]
32. [Treatment of multiple sclerosis. The present and the future. Study Group on Diagnosis and Therapy of Multiple Sclerosis]. Cazzato G; Antonello RM; Zorzon M; Torre P; Zivadinov R; Moretti R; Bragadin LM; De Masi R; Nasuelli D Recenti Prog Med; 1999 Oct; 90(10):538-44. PubMed ID: 10592740 [TBL] [Abstract][Full Text] [Related]
33. Histocompatibility antigens in multiple sclerosis patients participating in a multicentre trial of azathioprine. British & Dutch Multiple Sclerosis Azathioprine Trial Group. J Neurol Neurosurg Psychiatry; 1988 Mar; 51(3):412-5. PubMed ID: 3283297 [TBL] [Abstract][Full Text] [Related]
34. Azathioprine and steroids are not more effective in decreasing multiple sclerosis intra-blood-brain-barrier IgG synthesis than steroids alone. Staugaitis SM; Shapshak P; Myers LW; Ellison GW; Tourtellotte WW; Lee M Ann Neurol; 1985 Sep; 18(3):356-7. PubMed ID: 2996418 [TBL] [Abstract][Full Text] [Related]
39. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities. Stuart WH Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719 [TBL] [Abstract][Full Text] [Related]
40. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]